Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

Figure 3

Kaplan-Meier curves for median progression free survival (PFS) of colorectal cancer patients treated with irinotecan and cetuximab showing phosphorylated MAPK expression (-------) and without phosphorylated MAPK expression (——) in either primary tumours (A, 3 months vs. 6 months, p = 0.6) or metastases (B, 2.3 months vs. 8.6 months, p = < 0.0001).

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us